FDA Approves Novel Non-Opioid Treatment for Moderate to …
2 days ago · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
3 days ago · BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an ...
FDA Approves Journavx - Drugs.com
FDA Approves Journavx BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Journavx ™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
FDA Approves Journavx, First New Non-Opioid Pain Pill in Decades
2 days ago · FRIDAY, Jan. 31, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin. The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the Associated Press reported.
Vertex Announces FDA Approval of JOURNAVX ... - Business Wire
2 days ago · BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non ...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
2 days ago · BOSTON, January 30, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non ...
Journavx: Uses, Dosage, Side Effects, Warnings - Drugs.com
2 days ago · Journavx FDA approval was received on January 30, 2025, for treating moderate to severe acute pain in adults. This approval was based on positive results from Phase 3 clinical trials (VX21-548-101 and VX21-548-102), which showed that it effectively reduced acute pain for 48 hours after surgery.
FDA approves first new type of pain medication in 25 years
2 days ago · It will be sold under the brand name Journavx. A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. ... acting director of the FDA ...
FDA Approves Journavx Drug to Treat Pain Without Addiction Risk
2 days ago · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat ...
FDA approves Journavx, first novel painkiller in more than 20 …
2 days ago · FDA approves new, non-opioid painkiller Journavx The drug represents the first new class of pain medication in decades. January 30, 2025 at 7:28 p.m. EST Today at 7:28 p.m. EST
- Some results have been removed